The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio enables early detection of amyloid plaques through a non-invasive blood test

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, making the test the first to get signoff to aid in the early detection of the disease in the United States.

If you or someone you love is concerned about Alzheimer’s disease, the process of detecting its presence can involve a series of tests. As the Mayo Clinic’s history of the process reminds us, this is a step forward from the previous method of testing,